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Unveiling the molecular mechanism of SARS-CoV-2
main protease inhibition from 137 crystal structures
using algebraic topology and deep learning†
Duc Duy Nguyen,a Kaifu Gao,b Jiahui Chen,b Rui Wangb and Guo-Wei Wei

*bcd

Currently, there is neither eﬀective antiviral drugs nor vaccine for coronavirus disease 2019 (COVID-19)
caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Due to its high conservativeness and
low similarity with human genes, SARS-CoV-2 main protease (Mpro) is one of the most favorable drug
targets. However, the current understanding of the molecular mechanism of Mpro inhibition is limited by
the lack of reliable binding aﬃnity ranking and prediction of existing structures of Mpro–inhibitor
complexes. This work integrates mathematics (i.e., algebraic topology) and deep learning (MathDL) to
provide a reliable ranking of the binding aﬃnities of 137 SARS-CoV-2 Mpro inhibitor structures. We reveal
that Gly143 residue in Mpro is the most attractive site to form hydrogen bonds, followed by Glu166,
Received 21st August 2020
Accepted 30th September 2020

Cys145, and His163. We also identify 71 targeted covalent bonding inhibitors. MathDL was validated on
the PDBbind v2016 core set benchmark and a carefully curated SARS-CoV-2 inhibitor dataset to ensure

DOI: 10.1039/d0sc04641h

the reliability of the present binding aﬃnity prediction. The present binding aﬃnity ranking, interaction

rsc.li/chemical-science

analysis, and fragment decomposition oﬀer a foundation for future drug discovery eﬀorts.

1

Introduction

Starting in late Dec, 2019, the COVID-19 pandemic caused by
new severe acute respiratory syndrome coronavirus (SARS-CoV2) has infected more than 22 million individuals and has caused
more than 777 000 fatalities in all of the continents and over
213 countries and territories by August 19th, 2020. Under the
current global health emergency, researchers around the world
have engaged in the investigation of the diﬀerent drug targets of
SARS-CoV-2, such as the main protease (Mpro, also called
3CLpro), papain-Like protease (PLpro), RNA-dependent RNA
polymerase (RdRp), 50 -to-30 helicase protein (Nsp13) to seek
potential cures for this serious pandemic. To date, although
there are some vaccines undergoing the Phase III trials,1 their
safety and eﬃcacy are still unclear.2
The main protease, one of the best-characterized targets for
coronaviruses, attracts lots of research attention because it is
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very conservative and distinguished from any human gene. A
recent study shows that although the overall sequence identity
between SARS-CoV and SARS-CoV-2 is just 80%, the Mpro of
SARS-CoV-2 shares 96.08% sequence identity to that of SARSCoV.3 Therefore, we hypothesize that a potent SARS Mpro
inhibitor is also a potent SARA-CoV-2 Mpro inhibitor.
At this moment, more than 300 potential SARS-CoV Mpro
inhibitors with its binding aﬃnities are available in ChEMBL
database4 which can be considered as the potential SARS-CoV-2
Mpro inhibitors. Recently, total 146 crystal structures of SARSCoV-2 Mpro with its ligand complexes are released on the
Protein Data Bank (PDB).5 Among them, 137 crystal structures
have no available binding aﬃnities reported for various
reasons. However, the central dogma of drug design and
discovery concerns the molecular mechanism and binding
aﬃnity of drug target interactions. Knowing the binding aﬃnities and their ranking of 137 SARS-CoV-2 Mpro inhibitors is of
great signicance to the future design of anti SARS-CoV-2 drugs.
In this work, for the rst time, we predict the binding
aﬃnities of these 137 Mpro–inhibitor complexes by reformulating algebraic topology-based mathematics-deep learning
(MathDL) models, which have been the top competitor in D3R
Grand Challenges, a worldwide competition series in computer
aided drug design in the past three years.6 We generate reliable
poses for 141 Mpro inhibitors with binding aﬃnities but without
complex structures. Together with 44 other complexes, we
compose a set of 185 Mpro–inhibitor complexes, which is paired
with 17 382 protein–ligand complexes in PDBbind 2019 general
set. These datasets are utilized to construct 11 MathDL models

This journal is © The Royal Society of Chemistry 2020
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in single-task and multitask settings.6 One of these 11 MathDL
models has been validated by using the PDBbind v2016 core set
benchmark, achieving the top performance over all exiting
scoring functions. The other ten MathDL models have crossvalidated on a set of 185 Mpro–nhibitor complexes, showing
an averaged Pearson's correlation coeﬃcient of 0.73.
Notably, for covalent inhibitors, the scheme of covalent
irreversible inhibition of SARS-CoV/SARS-CoV-2 Mpro is presented below:
k1

k3

* EI ! E  I
EþI)
k2

The inhibitor rst binds to the protease noncovalently, then
a nucleophilic attacking by Cys145 leads to the formation of
a stable covalent bond between the protease and the inhibitor.7,8
The interaction depends on both the equilibrium-binding
constant Ki (designated as k1/k2) and the inactivation rate
constant for covalent bond formation k3. In this work, the
binding aﬃnity/IC50 assesses the rst step to form noncovalent
binding.
In a nutshell, the present work provides reliable binding
aﬃnity predictions and ranking of 137 SARS-CoV-2 inhibitors
that have crystal structures. It also oﬀers data curation and
validated models for exploring potential SARS-CoV-2 Mpro
inhibitors. Furthermore, this work explores diﬀerent possible
binding regions on the SARS-CoV-2 main protease and decode
the most favorable molecular fragments for the inhibitor
design.

2 Results and discussions
2.1

Results

This section is devoted to the utilization of our MathDL models
developed in Section 3.3 to predict the binding aﬃnities and
their ranking of SARS-CoV-2 inhibitors that do not have reported experimental aﬃnities. To reduce the role of 3D pose
prediction errors in our model, we use the SARS-CoV-2 inhibitors with X-ray structures available in the PDB for our study. We
manually search these ligands on the PDB and arrive at a set
consisting of 137 SARS-CoV-2 Mpro inhibitors having X-ray
crystal structures but lacking of experimental binding aﬃnities. We name this set SARS-CoV PDB-noBA (see Table 3). In this
experiment, we develop a MathDL model optimized from
PDBbind v2016 core set (see Section 3.3.1), ve MathDL-ALL
and ve MathDL-MT models obtained from 5-fold study on
the SARS-CoV BA set (see Section 3.3.2). The nal predicted
binding aﬃnity is the consensus of these 11 models. The top ten
inhibitors indicated by our models are shown in Table 1.
The most potent SARS-CoV-2 inhibitor found by our MathDL
models is the inhibitor Nol in complex 7c8t. Nol was synthesized by Yang and his colleagues,9 Nol is found remarkable
activities against SARS-CoV and HCoV.9 Specically, the dissociation constant Ki of Nol was found to be 0.053 mM against
SARS-CoV.9 Our MathDL reveals that Nol still inhibits SARSCoV-2 main protease with a potent aﬃnity at 0.30 mM.

This journal is © The Royal Society of Chemistry 2020

Binding aﬃnities of top 10 complexes in SARS-CoV PBDnoBA dataset predicted by our MathDL. “Pred. BA” indicates the predicted binding free energy in kcal mol1 and “Pred. IC50” is the corresponding IC50 in mM unit via the following conversion: Pred. IC50 ¼
10Pred. BA/1.3633  106
Table 1

PDBID

Pred. BA

Pred.
IC50

PDBID

Pred. BA

Pred.
IC50

7c8t
5rgl
6xhm
7bqy
5rfr

8.90
8.50
8.50
8.49
8.45

0.30
0.58
0.58
0.59
0.63

6z2e
6xbi
6xmk
5rh7
6xbh

8.43
8.34
8.33
8.32
8.27

0.66
0.76
0.78
0.79
0.86

Another important top potent SARS-CoV-2 inhibitor found by
our models is the Michael acceptor inhibitor N3 in complex
7bqy. Designed by Yang and his colleagues,8 N3 was found to
have viral activities against diﬀerent coronavirus Mpro such as
SARS-CoV and MERS-CoV.8,10 Specically, the dissociation
constant Ki of N3 was found to be 9.0 mM against SARS-CoV.8
Our MathDL reveals that N3 still inhibits SARS-CoV-2 main
protease with an even better aﬃnity at 0.59 mM. This nding is
consistent with the literature work11 showing that N3 is a potent
inhibitor of COVID-19 virus Mpro.
The inhibitor Qys in the complex 6xmk is also noticeable.
Our predicted IC50 is 0.78 mM. Soon aer we made the prediction, on August 12th, 2020, Rathnayake et al.12 released another
Qys-main protease complex with PDB ID 6w2a and also reported
the IC50 of Qys to SARS-CoV-2 is 0.45 mM, which is close to our
prediction.
It is worth pointing out, except for the inhibitor T9j in the
complex 5rg1, the rest of inhibitors reported in Table 1 are
covalent inhibitors, which irreversibly form covalent bonds with
Cys145 of the main protease (see discussion in Section 2.2.2).
However, our models only predict the non-covalent binding
aﬃnity which is measured before the enzyme deactivation. The
predicted binding aﬃnities of all 137 complexes in SARS-CoV
PBD-noBA dataset from various MathDL models are presented
in Table S8 in ESI.† In this table, we also supply the synthetic
accessibility score (SAS), partition coeﬃcient log P, and solubility log S for each small molecule. Except for SAS obtained via
RDKit,13 log P and log S are evaluated by our TopP-S model.14

2.2

Discussion

2.2.1 Binding site analysis. Based on the crystal structure
information of 137 complexes in SARS-CoV PDB-noBA set, we
have identied 13 distinct binding site regions of the SARS-CoV2 main protease as illustrated in Fig. 1. Those binding pockets
are denoted by Pi, i ¼ 1, 2, ., 13. Fig. 2a reveals that binding
pocket P1 is the most common binding region of the SARS-CoV2 main protease, which attracts around 80.2% of ligands in the
SARS-CoV PDB-noBA data set of 137 complexes. This nding is
no surprise since the binding pocket P1 shares similar active
sites to its predecessor, i.e. SARS-CoV Mpro. Specically, P1
encompasses His141 and Cys145 catalytic dyad which are
imperative to the substrate-binding mechanism.8 In additions,
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Fig. 1 All binding site pockets observed from 137 inhibitors in SARSCoV PDB-noBA set.

the substrate-binding residues Tyr161 and His163 (ref. 15) are
covered in P1. Binding pockets P2, P3, P5, P7, P8, and P10 are the
least favor sites consisting of only one ligand. The rest of the
binding pockets involve no more than 7 ligands. To study the
correlation of the binding regions to the binding free energy, we
present the box plot in Fig. 2b to illustrate the energy values
through their quartiles.
The prevailing binding pocket P1 is the best region on the
SARS-CoV-2 Mpro for inhibitor design with the median binding
energy being 7.22 kcal mol1. Nol is the best inhibitor
candidate for the binding site P1 with predicted aﬃnity found to
be 8.90 kcal mol1. Other binding regions such as P4, and P11

Edge Article
are less common but show their adequate eﬀects on the binding
mechanism with their best energy binding aﬃnities calculated
at 7.28 kcal mol1 and 6.80 kcal mol1, respectively. These
potential binding sites can guide drug combination to inhibit
coronavirus Mpro eﬀectively.
2.2.2 Interaction analysis. By looking further into the
interactions between the top inhibitors and the main protease,
we have found that Nol, V2m, N3 are peptidomimetic inhibitors, they form as many as 8, 8, 9 hydrogen bonds respectively to
the nearby residues and also all form 1 covalent bond with
Cys145 as listed in Table 2 and depicted in Fig. 3. All these
hydrogen bonds justify their potency of the rst step of noncovalent binding to the main protease complex and conrms
the robustness of our MathDL models; the covalent bonds make
the binding irreversible. We also notice that these three inhibitors share two common hydrogen bonds to His163, His164 (see
Table 2, Fig. 3a, c and d). Therefore, they have some similar
predicted binding energies, especially 6xhm and 7bqy at
8.50 kcal mol1 and 8.49 kcal mol1, respectively.
This examination manifests how well our models preserve
and capture the physical and chemical properties described in
intermolecular bonding interactions. Furthermore, the ligand
T9J that binds to Mpro in complex 5rg1 with a quite close
binding energy at 8.50 kcal mol1 forms diﬀerent hydrogen
bonds in comparison to three previously mentioned inhibitors
(see Table 2). Since our models only concern the non-covalent
binding aﬃnity, the lack of covalent bond in 5rg1's interactions does not downgrade its binding strength. With two relatively large hydrogen bonding distances (O2-His163: 3.05 Å, O3Glu166: 3.38 Å (see Fig. 3d)), the binding aﬃnity of 5rg1 is still
comparable to the top inhibitors indicating the important roles
in acquiring the hydrogen bonds to these residues in the main
protease's binding process.
In the top 10 inhibitors as listed in Table 1, T9J in the
complex 5rg1 is only one non-covalent inhibitor. The rest
belongs to the class of targeted covalent inhibitors (TCI) in
which they interacts with the protein residues, i.e., cysteine, to
form a covalent complex strongly neutralizing target's function.
However, the major disadvantage of TCIs is the association with
the high toxicity risks.16 TCIs' strong covalent bond can irreversibly modify the unintended protein targets in the human
body. As a result, the top covalent inhibitors in SARS-CoV PBDnoBA dataset may have little chance to become approved

Fig. 2 (a) Distribution of 137 ligands across 13 distinct binding sites; (b) Box plot of predicted binding energies (kcal mol1) of all inhibitors in each
binding site.
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Interaction analysis in the binding pockets of top 4 complexes in term of binding aﬃnity predicted by our MathDL models

PDB ID

Ligand ID

Hydrogen bond

Covalent bond

7c8t
5rg1
6xhm
7bqy

Nol
T9J
V2m
N3

His163, His164, Cys145, Gln189, Gly143, Glu166
His163, Glu166
His163, His164, Cys145, Gln189, Phe140
His163, His164, Cys145, Gln189, Thr190, Glu166, Phe140, Gly143

Cys145

market drugs in comparison to their non-covalent counterparts
such as T9J in 5rg1.
Due to the popularity of the binding site P1 among 137
interested inhibitors, we mainly analyze the interaction network
around the residues in that region. Out of 110 molecules
binding to P1, there are 103 inhibitors forming at least one
hydrogen bond to the nearby amino acid in the SARS-CoV-2
main protease. We have identied 20 diﬀerent residues in the
binding pocket P1 composing hydrogen bonds to these small

Cys145
Cys145

molecules. Fig. 4 illustrates the frequency of these 20 residues
across 110 inhibitors. Based on Fig. 4, Gly143 residue is the
most attractive site to form the hydrogen bond. It appears in
53.6% of 110 intermolecular bonding interactions, followed by
Glu166 residue with a frequency of 39.1%; residue Cys145 and
His163 also occupy 38.2% and 30.9%, respectively. It is worth
noting when these molecules form a hydrogen bond with
Cys145, they also constitute another hydrogen bond with
Gly143. In all cases, both these residues share the same

Fig. 3 The interactions between the top 4 inhibitors in the SARS-CoV PBD-noBA dataset and SARS-CoV-2 Mpro: (a) 7c8t; (b) 5rg1; (c) 6xhm; and
(d) 7bqy. Inhibitors are shown in the purple color. Hydrogen bonds are marked in dashed green lines, and covalent bonds are depicted in solid
blue lines. All interactions are shown with the distance information in Å.

This journal is © The Royal Society of Chemistry 2020
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Fig. 4 Popularity of amino acids in the binding site P1 constituting the
hydrogen bonds with ligands.

hydrogen-bond acceptor. Besides the hydrogen bond network,
71 ligands in the SARS-CoV PDB-noBA dataset form a covalent
bond to g-sulfur of Cys145. Except the second one, all the others
in the top 10 inhibitors are equipped with that covalent bond
(see Table S8 in ESI†).
Furthermore, we are interested in the binding energy
distribution associated with the interaction network. Fig. 5
depicts the violin plot of that distribution across four categories, namely no H-bond (no hydrogen bond), H-bond (at least
one hydrogen bond), no cov. bond (no covalent bond), and cov.
bond (at least one covalent bond). Hydrogen bond interactions
that are expected to play an important role in the binding
mechanism are well captured in our MathDL models. Specically, while the average energy of inhibitors having no hydrogen
bond is 6.62 kcal mol1, the average energy of ones with
hydrogen bond is as low as 7.23 kcal mol1.
It is noted that our MathDLs only measure the non-covalent
binding aﬃnity. The covalent bond appearing at the nal
covalent complex is not properly accounted for in our framework. Therefore, it is expected that our models sometimes
overestimate the covalent-bond inhibitors over the noncovalent-bond candidates. Fig. 5 reveals molecules in the

Violin plot of the predicted binding energies for 110 inhibitors
binding to the binding site P1 classiﬁed into 4 categories, namely no Hbond (no hydrogen bond), H-bond (at least one hydrogen bond), no
cov. bond (no covalent bond), cov. bond (at least one covalent bond).
The mean is in the orange color, the median is in the blue color, and
the minimal and the maximal values are both in the black color.
Fig. 5

12040 | Chem. Sci., 2020, 11, 12036–12046
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group of covalent bonds generally are predicted with lower
binding energy with an average being 7.42 kcal mol1 in
comparison to 6.89 kcal mol1 averagely measured on ones
without covalent bonds.
2.2.3 Fragment analysis. To design the lead molecules, it is
of importance to have promising fragments from existing
inhibitors against the drug targets. Therefore, in the present
work, we study all the fragments decomposed from 110 inhibitors attached to the binding site P1. To carry out this task, we
utilize BRICS algorithm17 via RDkit.13 In BRICS model, there are
16 chemical environments indicated by linkers denoted by L1,
L2, ., L16. The BRICS decomposition gives raise to a total of 185
unique fragments, which are all presented in Table S9 in ESI.†
Fig. 6 illustrates top 12 common fragments in terms of their
frequencies. Noting that the second frequent fragment, L1–
C(C)]O, oen constitutes a hydrogen bond with Gly143 and in
many cases forms a covalent bond with Cys145.

3 Materials and methods
3.1

Datasets

Our deep learning-based scoring function, MathDL, was trained
on public databases including PDBbind18 and ChEMBL.4 The
PDBbind sets contain all complexes with crystal structures
deposited in the PDB with the binding aﬃnities not limited to
Kd, Ki, and IC50 reported in the literature. In this work, we
employ the PDBbind v2019, the latest version of its generation.
The v2019 version of the PDBbind consists of 17 679 protein–
ligand complexes. However, the data preprocessing of the
MathDL32 only retains 17 382 complexes. Among them, there
are 10 485 ligands measured in Kd/Ki and 6537 ligands
measured in IC50.
ChEMBL is another manually curated database of bioactive
molecules. Currently, ChEMBL contains more than 2 million
compounds in the SMILES string format. Excluding 30 main
protease inhibitors in PDBbind data, we have found other 277
small molecules on ChEMBL with reported Kd/IC50. Additionally, we have found more than 300 other SARS-CoV main
protease inhibitors from literatures.18–20,25–31 In total, there are
more than 600 ligands bound to SARS-CoV/SARS-CoV-2 main
protease having the experimental binding aﬃnities; among
them, there are 44 crystal structures. For compounds without
the crystal structures, MathPose6 is utilized to generate their 3D
conformations. The predicted 3D coordinates of these structures are presented in the SDF format and available in ESI.†
Currently, there are roughly 137 ligands forming crystal
complexes with the SARS-CoV-2 main protease on PDB without
the report of the experimental inhibitor activities. Most of them
are deposited by the PanDDA analysis group (https://
pandda.bitbucket.io/#).
To serve model validation purposes, we classify the selected
data into ve diﬀerent groups as listed in Table 3. Specically,
PDBbind v2019 is the biggest set in this compilation with its
PDB IDs and experimental binding aﬃnities listed in Table S1
in ESI.† PDBbind v2016 core set is a subset of PDBbind v2019
and is formed by 290 complexes representing all protein classes
in the rened set of PDBbind v2016.18,33 The PDB IDs of all

This journal is © The Royal Society of Chemistry 2020
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Fig. 6 Fragment frequencies based on BRICS decomposition of 110 inhibitors of binding site pocket P1. Li is the link atom of a certain type
described in ref. 17.

Table 3

A summary of our selected data sets

Data name

Data size

Descriptions

References

PDBbind v2019
PDBbind v2016 core set
SARS-CoV PDB

17 382
290
192

18
18
5, 19 and 20

SARS-CoV PDB-BA

44

SARS-CoV PDB-noBA

137

SARS-CoV 2D

141

SARS-CoV BA

185

Partial PDBbind general set v2019
PDBbind v2016 core set
Inhibitors of SARS-CoV/SARS-CoV-2
Mpro having X-ray crystal structures
Inhibitors of SARS-CoV/SARS-CoV-2
Mpro having X-ray crystal structures
and experimental binding aﬃnities
Inhibitors of SARS-CoV-2 Mpro
having X-ray crystal structures but
lacking of experimental binding
aﬃnities
Inhibitors of SARS-CoV/SARS-CoV-2
Mpro having only 2D structures
Inhibitors of SARS-CoV/SARS-CoV-2
Mpro having experimental binding
aﬃnities

complexes in the PDBbind v2016 core set are provided in Table
S2.† We also collect all Mpro complexes of SARS-CoV/SARS-CoV-2
on the PDB, denoted by SARS-CoV PDB, which results in a total
of 192 structures (see Table S3†). Among them, there are 44
ligands with the report of experimental binding aﬃnities
denoted by SARS-CoV PDB-BA (see Table S4†). Furthermore, we
are interested in the set of SARS-CoV-2 Mpro complexes in the
aforementioned SARS-CoV PDB set but their aﬃnities are not
presented or undisclosed. We call this set SARS-CoV PDB-noBA
with PDB IDs listed in Table S5.† To enrich our training data
targeting SARS-CoV/SARS-CoV-2 main protease inhibitors, we
gather some inhibitors reported on the literature.4,25 For those
compounds with only 2D information, we limit ourselves to
ones having the similarity score based on the path-based
ngerprint FP2 no lower than 0.6 to at least one inhibitor in

This journal is © The Royal Society of Chemistry 2020

5, 18–23

5, 18–20, 24

4, 19, 20, 25–31
5, 18–20, 26–31

the SARS-CoV PDB set. As a result, we arrive at a set of 141
structures named SARS-CoV 2D (see Table S6†). Combining
SARS-CoV PDB-BA and SARS-CoV 2D data sets, we nalize
a reliable database focusing on SARS-CoV/SARS-CoV-2 main
protease inhibitors. Notice that the binding aﬃnities in this set
are all reported in IC50. Table S7 in ESI† presents the PDB IDs as
well as the experimental binding energies of these ligands.

3.2

Methods

3.2.1 MathDL. The MathDL models developed in this work
are reformulated from our early model bearing the same name.
MathDL was designed for the prediction of various druggable
properties of 3D molecules.6 In the past three years, MathDL has
been proved to be the top competitor in D3R Grand Challenges

Chem. Sci., 2020, 11, 12036–12046 | 12041
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Fig. 7 A framework of MathDL energy prediction model which integrates advanced mathematical representations with sophisticated CNN
architectures.

(https://drugdesigndata.org/about/grand-challenge), a worldwide competition in computer-aided drug design. In the present
work, we have, for the rst time, develop a multitask MathDL
(MathDL-MT) to handle the Mpro inhibitor dataset. We have also
extended our earlier MathDL by including all diﬀerent datasets
(MathDL-All). Fig. 7 depicts the framework of the MathDL in
which the element-specic algebraic topological representations are integrated with the convolutional neural network
(CNN) aiming to predict varied druggable properties such as
toxicity, binding aﬃnities, etc.
3.2.1.1 Algebraic topology-based representations. Algebraic
topology studies the topological spaces with the use of abstract
algebra, which can dramatically simplify the geometric
complexity. Persistent homology (PH) is one of the algebraic
topology approaches which has the capacity to track the multiscale topological information over diﬀerent scales along with
ltration by characterizing independent components, rings,
and higher dimensional voids in space.34 In this section, we will
briey review the algebraic topology-based representations.
Additionally, since we are dealing with the protein–ligand
system, therefore, the biological considerations will take into
account as well.
Simplex. The q-simplex denoted as sq is the convex hull of q +
1 aﬃnely independent points in ℝn ðn $ kÞ. For example, the 0,
1, 2, and 3-simplex is considered as a vertex, an edge, a triangle,
and a tetrahedron, respectively. We call the convex hull of each
non-empty subset of q + 1 points the face of sq, and each points
are also called the vertices.
Simplicial complex. A set of simplices is a simplicial complex
denote K which satises that every face of a simplex sq ˛ K is
also in K and the non-empty intersection of any two simplices in
K is the common face for both.

12042 | Chem. Sci., 2020, 11, 12036–12046

Chain complex. A formal sum of q-simplices in simplicial
complex K with coeﬃcients in an algebraic eld (typically ℤ2 ) is
a q-chain. A set of all q-chains of the simplicial complex K
equipped with an algebraic eld is called a chain group and
denoted as Cq(K). The boundary operator is dened by vq: Cq(K)
/ Cq1(K) to relate the chain groups. More specically, we
denote sq ¼ [v0, v1, ., vq] for the q-simplex spanned by its
vertices, and then the boundary operator can be represented as:
vq sq ¼

q
X

ð1Þi sq1 i :

(1)

i¼0

Here, sq1 i ¼ ½v0 ; .; ^vi ; .; vq  is the (q  1)-simplex with vi being
omitted. The sequence of chain groups connected by boundary
operators is called the chain complex and expressed as:
vqþ2

vqþ1

vq

vq1

/ ! Cqþ1 ðKÞ ! Cq ðKÞ ! Cq1 ðKÞ ! /
The q-cycle group Zq(K) and the q-boundary group Bq(K) are
dened as Zq(K) ¼ ker(vq) ¼ {c ˛ Cq(K)|vqc ¼ B} and Bq(K) ¼
im(vq+1) ¼ {vq+1c|c ˛ Cq+1(K)}. The q-th homology group is the
quotient group Hq(K) ¼ Zq(K)/Bq(K). Moreover, the rank of q-th
homology group can be computed as rankHq(K) ¼ rankZq(K) 
rankBq(K), which is denoted as the q-th Betti number bq. To be
notice that the q-th Betti number count the number of qdimensional holes that can not be continuously deformed to
each other.
Persistent homology. A ltration of a simplicial complex K is
a nested sequence of subcomplexes of K such that B ¼ K0 4 K1
4 K2/4 Km ¼ K. Then the p-persistent qth homology group of
Kt is dened as:
Hqp(Kt) ¼ Zq(Kt)/(Bq(Kt+p) X Zq(Kt)).

(2)
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Here the rank of Hqp(Kt) counts the number of q-dimensional
holes in Kt that are still alive in Kt+p, which is called the ppersistent qth Betti number. The persistent homology not only
records the topological information at a specic conguration,
but also tracks the changes along with the ltration parameters.
More specically, the topological changes will be preserved in
the persistent barcodes. In MathDL, we make use of the
persistent homology barcodes by dividing them into bins and
calculating the birth, death, and persistence incidents in each
bin to enrich our algebraic topological representations.
3.2.1.2 Element specic considerations. The protein–ligand
complex is structural and also biological. The persistent
homology provides a theoretical approach to encode highdimensional spatial data of protein–ligand complexes into
algebraic topological representations. In this section, we
address the biological considerations for biomolecular
complexity. There are many kinds of interactions that exist in
the protein–ligand complex, such as electrostatics, hydrogen
bonds, and hydrophobic eﬀects. Although persistent homology
can capture the interactions among the nearest neighbors, the
long-range interactions will be hindered. This diﬃculty can be
avoided via the deployment of the element-specic attention.32
There are 4 commonly atom types in protein, namely C, N, O, S,
and there are 11 commonly atom types in ligand, including
C, N, O, S, P, F, Cl, Br, I, H, B. We include Boron in the ligand
atom type consideration since it appears in more than 200 small
compounds in our training data. The general framework of
MathDL is depicted in Fig. 7 under exemplied steps. In addition, the details of the deep learning architecture of the current
MathDL is oﬀered in Fig. S1.† For the details of feature
descriptions as well as the deep learning architecture, interested readers are referred to our previous work.32
3.2.2 MathPose. MathPose, a 3D pose predictor that
converts SMILES strings into 3D poses with references of target
molecules, is the top performer in D3R Grand Challenge 4 (GC4)
in predicting the poses of 24 beta-secretase 1 (BACE) binders.6
For one SMILES string, around 1000 3D conformations can be
generated by various docking soware tools such as GOLD,35
Autodock Vina,36 and GLIDE.37 Moreover, a selected set of
known complexes is re-docked by three aforementioned docking soware packages to generate at least 100 decoy complexes
per input ligand used in the machine learning training set. The
machine learning labels will be the calculated root mean
squared deviations (RMSDs) between the decoy and native
structures for the training data of the pose selection task.
Furthermore, MathDL models will be set up and applied to
select the top-ranked pose for the given ligand. Besides the GC4
challenge, our models have outperformed state-of-the-art
scoring functions at the docking power challenge on CASF2007 and CASF-2013 benchmarks.33 Those established results
attest to the credibility of our MathPose on the 3D structure
prediction of small molecules.

3.3

Validations

3.3.1 PDBbind v2016 core set benchmark. In this validation task, we will testify our model against 290 complexes in the
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PDBbind v2016 core set. This is a prevalent test set to assert the
scoring ability of a binding aﬃnity prediction model and has
attracted lots of research groups to devote the eﬀort to improve
the Pearson's correlation coeﬃcient (Rp) and Kendall's tau (s)
on this core set performance.18,42,43 In the current work, we
merge the PDBbind v2019, SARS-CoV PDB-BA, and SARS-CoV 2D
sets but removing the duplicates and excluding the PDBbind
v2016 core set complexes to attain a training set of 17 211
complexes. MathDL with the architecture described in Section
3.2.1 is trained on those complexes. The resulting model is
utilized to predict the binding aﬃnity of 290 structures in the
PDBbind v2016 core set.
With the purpose of exploring the most optimal model for
this benchmark, MathDL is trained for 1000 epochs. Then, we
pick the epoch based on the root-mean-squared error (RMSE) of
the PDBbind v2016 core set prediction. We have found that
MathDL achieves the smallest RMSE in this experiment at 140
epochs. Specically RMSE, Rp, and s metrics on the v2016 core
set are 1.56 kcal mol1, 0.858, and 0.671, respectively. Meanwhile, the training accuracy is 0.387 kcal mol1 in terms of
RMSE and its Pearson's correlation coeﬃcient is Rp ¼ 0.994.
These performances reveal that our MathDL converges very fast
and with only 140 epochs and maintains a good balance
between training and testing accuracies. This is a state-of-theart performance since our MathDL is ranked in the second
place in comparison to 33 other scoring functions (see Fig. 8). It
is noted that the top model is TopBPcon. published in our
previous work32 with Rp ¼ 0.861. TopBPcon. is the consensus of
gradient boosted tree and deep learning-based models. If only
the deep learning framework is considered, the performance of
TopBP (denoted by TopBP-DL) on the core set of PDBbind v2016
is Rp ¼ 0.848.
It is worth mentioning that except for our MathDL, all
machine learning-based scoring functions listed in Fig. 8 were
trained on the PDBbind v2016 rened set of 3767 complexes. As
mentioned above, the current MathDL is compiled on a much
larger training set comprised of 17 211 complexes selected from
PDBbind v2019 and SARS-CoV BA data. Even the present
MathDL has not outperformed its predecessor, i.e., TopBPcon.,
MathDL is still a preference model since it is trained on
a diverse data set covering various protein families and diﬀerent
binding energy ranges. As a result, it is expected to deliver more
reliable predictions on the SARS-CoV-2 inhibitor, especially
when this main protease family is not included in the training
data of previous TopDL models. The resulting MathDL model is
labeled as MathDL-Core2016 and is utilized to predict aﬃnities
of complexes in SARS-CoV PDB-noBA in Section 2.1.
3.3.2 5 fold cross-validation on SARS-CoV BA set. In this
section, we testify the performance of our MathDL against 185
inhibitors in the SARS-CoV BA set aforementioned in Table 3.
Among those ligands, there are 44 X-ray crystal structures and
the rest are in 2D SMILES strings. We employ MathPose to
predict 3D structures of those 2D ligands. To carry out the
validation, we randomly split the SARS-CoV BA set into 5 nonoverlapped folds. In each fold prediction task, MathDL trains
on the partial data of SARS-CoV BA in conjunction with
PDBbind v2019 set. This situation results in two diﬀerent ways
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Fig. 8 The Pearson correlation coeﬃcient of various scoring functions on PDBbind v2016 core set benchmark. Our MathDL is in red. The
performances of other models that are in green are taken from ref. 18, 32, 38–41. TopBPcon., the consensus model in our published work,32
attains the highest Rp at 0.861. The current MathDL is followed with the second highest Rp at 0.858 and RMSE ¼ 1.56 kcal mol1. The third place in
the list is another TopBP model, TopBP-DL, solely based on the deep learning architectures and its reported Rp is 0.848.32 It is noted that all of the
machine learning based scoring functions in this comparison were trained on the PDBbind v2016 reﬁned set of 3767 complexes except for our
MathDL. Explicitly, MathDL is trained on a much larger training set consisting of 17 211 complexes picked out from the PDBbind v2019 set and
SARS-CoV BA set.

of training our MathDL model. The rst approach is a traditional MathDL architecture with the training set combining
both SARS-CoV BA and PDBbind v2019 complexes. The second
model makes use of multi-task learning.44 In each epoch, the
weights of the MathDL architecture are learned through the
information from PDBbind v2019 set, then only the fully connected layers are trainable when learning SARS-CoV BA structures. Finally, we come up with 10 diﬀerent MathDL models in
which the traditional MathDL frameworks are labeled as
MathDL-All-i and multi-task MatDL is named MathDL-MT-i
with i running from 1 to 5. In each model, aer 100 epochs, we
start monitoring which epoch that helps our model achieve the
smallest RMSE on the test set.
Table 4 reveals that MathDL-All models are well trained with
the averaged accuracy RMSE ¼ 0.286 kcal mol1, Pearson's
correlation coeﬃcient Rp ¼ 0.994, and Kendall's tau s ¼ 0.934.
Their averaged performances on test data across 5-fold of the
SARS-CoV BA set are found to be Rp ¼ 0.729, s ¼ 0.540, and

RMSE ¼ 0.789 kcal mol1. These results endorse the reliability
of these models in the binding aﬃnity prediction of SARS-CoV/
SARS-CoV-2 inhibitors. Table 4 also lists the training and testing
performances of ve multi-task learning models. The averaged
training performance of the MathDL-MT model is Rp ¼ 0.995, s
¼ 0.941 and RMSE ¼ 0.275 kcal mol1. The accuracy of the
multi-task architecture on the test sets is similar to MathDL-All
with Rp ¼ 0.727, s ¼ 0.532, and RMSE ¼ 0.822 kcal mol1. With
these promising results, it is encouraging to carry out MathDL
models to predict unknown binding aﬃnities of SARS-CoV/
SARS-CoV-2 inhibitors. It is worth noting that if the 5-fold
cross-validation is conducted purely on the SARS-CoV BA set,
the average Rp and s are as low as 0.561 and 0.388, respectively.
These results strongly support the inclusion of diverse information such as PDBbind v2019 in conjunction with sophisticated deep learning architectures to achieve the accurate
binding energy prediction of Mpro inhibitors.

4 Conclusion
5-fold Performances of MathDL-All and MathDL-MT on
SARS-CoV BA set
Table 4

MathDL-ALL

Fold 1 (train)
Fold 1 (test)
Fold 2 (train)
Fold 2 (test)
Fold 3 (train)
Fold 3 (test)
Fold 4 (train)
Fold 4 (test)
Fold 5 (train)
Fold 5 (test)
Average (train)
Average (test)

MathDL-MT

Rp

s

RMSE

Rp

s

RMSE

0.992
0.792
0.995
0.625
0.991
0.771
0.996
0.618
0.995
0.838
0.994
0.729

0.923
0.534
0.943
0.498
0.917
0.572
0.948
0.397
0.941
0.699
0.934
0.540

0.327
0.682
0.266
0.866
0.367
0.758
0.240
0.874
0.231
0.767
0.286
0.789

0.996
0.818
0.996
0.689
0.994
0.767
0.997
0.642
0.991
0.719
0.995
0.727

0.949
0.534
9.948
0.538
0.934
0.593
0.951
0.472
0.921
0.524
0.941
0.532

0.253
0.680
0.236
0.826
0.327
0.802
0.177
0.901
0.380
0.900
0.275
0.822
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SARS-CoV-2 main protease (Mpro) is the most favorable target
for COVID-19 drug discovery due to its conservative nature and
low similarity with human genes. Structure and binding aﬃnity
of protein–drug complexes are of paramount importance for
understanding the molecular mechanism in drug discovery.
However, there are only two SARS-CoV-2 Mpro inhibitor structures available with binding aﬃnities, highlighting current
challenges in COVID-19 drug discovery.
This work presents the reliable binding aﬃnity prediction
and ranking of 137 Mpro–inhibitor crystal structures that have
no reported experimental binding aﬃnity. We rst curate a set
of more than 600 Mpro inhibitors with binding aﬃnities from
public resources, such as PDBbind, ChEMBL and the scattered
literature. Among these inhibitors, 141 are retained based on
their high similarity with available Mpro–inhibitor complex
structures and built with three dimensional (3D) poses using
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our MathPose.6 Together with 44 another SARS-CoV or SARSCoV-2 Mpro–inhibitor complexes, we compose a training set of
185 reliable SARS-CoV-2 Mpro–inhibitor complexes. Our earlier
MathDL models are reformulated with algebraic topology to
accommodate 119 new complexes and 17 382 complexes from
the PDBbind v2019 general set in both single-task and multitask
settings, which have never been available before. The resulting
MathDL models are rigorously validated via PDBbind v2016
core set benchmark in which it outperforms state-of-the-art
models in the literature. Most importantly, our MathDL achieves promising cross-validation accuracies on the SARS-CoV
family inhibitors with the averaged Pearson's correlation coefcient as high as 0.73.
Additionally, the present work unveils that Gly143 of Mpro is
the most attractive region to form hydrogen bonds, followed by
Glu166, Cys145, and His163. There are 71 inhibitors interacting
with SARS-CoV-2 Mpro to form covalent complexes. Those
covalent bonds are mostly composed between dicarbon
monoxide groups in inhibitors and g-sulfur on Cys145. There
are only one non-covalent complex in our top 10 ranked, namely
5rg1. To provide a potential resource for lead molecule design,
we employ the BRICS algorithm to decompose all the inhibitors
of the prominent binding site on Mpro and obtain 185 unique
fragments.
The predicted binding aﬃnities and their ranking of 137
Mpro–inhibitor crystal structures, the bonding analysis, and the
fragment decomposition have signicantly extended current
knowledge and understanding of SARS-CoV-2 Mpro and inhibitor interactions and, thus oﬀered valuable information toward
COVID-19 drug discovery.
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